Janssen Pharmaceuticals has selected a subsidiary of Pasadena-based Jacobs Engineering Group to provide engineering services for a new active pharmaceutical ingredients (API) manufacturing plant at Janssen's existing Little Island site in Ireland. The facility will expand manufacturing operations for existing products and will produce one new aseptic API product. Janssen, based in Titusville, N.J., is a subsidiary of Johnson & Johnson.
Vista-based BioFilm Inc.'s new headquarters will be built on 3.52 acres in the Palomar Corporate Center in Vista, Calif. The 60,860-sf leased facility, developed by Moxie Pacific Palomar LLC, will be ready for occupancy by Jan. 1, 2004.
Biopharmaceutical company Centocor has leased an additional 46,000 sf in Radnor, Pa., bringing its total site operations up to 204,000 sf. Centocor is a subsidiary of New Jersey-based Johnson and Johnson. The facility, owned by The Rubenstein Co., was vacated by Wyeth in its relocation to a new campus in Collegeville in Montgomery County, Pa.
More than doubling its West Coast capacity, Cardinal Health will expand its San Diego sterile manufacturing facility by 70,000 sf. The expansion will enable Cardinal to increase its production of freeze-dried pharmaceuticals and liquid products. The project, which will provide space for an additional 125 employees, will begin later in 2003. Cardinal, based in Dublin, is a global provider of goods and services to the health care industry.
EMD Pharmaceuticals, the U.S. subsidiary of Darmstadt, Germany-based Merck KGaA, will construct a $300-million biomanufacturing plant in Jena, Germany. The 200,000-sf facility will manufacture cancer drugs.
Altana AG, a Konstanz, Germany-based drug maker, opened its 25,000-sf Waltham, Mass., research offices in late January 2003. Part of a collaboration with Munich-based GPC Biotech, Altana has committed $120 million to develop its U.S. Genomics Research Institute in subleased space in GPC's 85,000-sf Waltham facility.
Hisamitsu Pharmaceutical is developing 6,400 sf of office and manufacturing space in Carlsbad, Calif. The facility, designed by JKE Design and Associates and built by Biostruct, will also house relocated tissue culture, biology and chemistry labs.
PPD, a Wilmington-based pharmaceutical and biotech discovery and development firm, has leased an additional 25,000-sf in Morrisville. PPD currently occupies four buildings totaling 283,000-sf at its expanding Triangle campus.
Tokyo, Japan-based drugmaker Eisai Co. is planning to begin construction in early 2004 on a $65-million R&D center in Andover, Mass. The facility will enable Eisai to double its U.S. basic research staff to as many as 170 employees. Eisai will also spend approximately $9-million on a second production line for drugs used in clinical testing at one of its existing U.S. research facilities.
Andrx Corp. paid a Bristol-Myers Squibb Co. affiliate company $28-million for a 500,000-sf manufacturing facility in Morrisville. Over the next five years Andrx will engage in a complete renovation and re-equipping of the building estimated to cost $85-million.
Wilmington-based Pharmaceutical Product Development (PPD) is negotiating construction of an additional 70,000-sf facility at its Barclay Commons campus with developer Cameron. PPD, a contract research firm for pharmaceutical and biotech companies, has two existing buildings totaling 60,000-sf and 70,000-sf at the site.
Icon Clinical Research will consolidate operations totalling 25,000 sf from offices in San Bruno and Mountain View with a move in early 2003 to a five-story R&D and office building in Redwood City. Icon provides biometric and clinical research services for the biotech and pharmaceutical industries.
Bayer Diagnostics, a division of Bayer Corp., has vacated seven East Bay locations to consolidate operations in a recently completed 75,000-sf Berkeley building. Located in Wareham Development's Aquatic Park where Bayer Diagnostics will continue to occupy space in two adjacent buildings, the five-story facility was built to the division's specifications.
Cedra Clinical Research opened its new $1.4-million, 23,500-sf clinical trials research center in Austin in November 2002. Increasing Cedra's number of beds from 60 to 100, the center features amenities for study participants including space for recreational activities and movie screenings, a study area with computers, and comfortable furniture. Cedra conducts clinical trials in various therapeutic areas such as asthma and allergy research, hypertension, and diabetes.
Idec Pharmaceuticals broke ground in October 2002 on its new five-building corporate headquarters and laboratory facility in San Diego's University Towne Center. San Diego-based Cisterra Partners is developer of the 42.6-acre project, with Hellmuth, Obata + Kassabaum of St.
